Serum selenium in patients with ovarian cancer during and after therapy

Publisher Website
Google Scholar
Abstract
Serum concentrations of selenium were determined by atomic absorption spectrophotometry in 40 patients with ovarian cancer in association with and after surgical and cytostatic therapy. Patients with ovarian cancer had significantly (p <0.001) lower serum concentrations (mean±SE) of selenium (0.93 ±0.04 μmol/1) than age-, weight- and place of residence-matched control subjects (1.22 ±0.03 μmol/1). In clinical stage IV disease there was a lower serum level of selenium (0.82 ±0.07 μmol/1) than in clinical stages I and II combined (1.00±0.04 μmol/l). Serum selenium concentrations also showed a tendency to follow the outcome of the disease; an increase in patients with remission and a decrease in patients with progressive disease, probably because of nutritional reasons.